|Bid||338.9300 x 1100|
|Ask||339.2200 x 1800|
|Day's Range||337.8000 - 341.5300|
|52 Week Range||249.1700 - 388.6700|
|PE Ratio (TTM)||24.11|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On Monday, GuruFocus' High Quality Screener listed three biotechnology companies that offer good potential ahead of the fourth quarter: Biogen Inc. (BIIB), Gilead Sciences Inc. (GILD) and Novo Nordisk A/S (NVO). Warning! GuruFocus has detected 4 Warning Signs with ORCL. Berkshire Hathaway Inc. (BRK-A)(BRK-B) CEO Warren Buffett (Trades, Portfolio) has stressed several times that key investing criteria include predictable earnings and strong economic moat.
Solid Biosciences (SLDB) incurred a net loss of $17.98 million in the second quarter of 2018, which compares to a net loss of $11.31 million in the second quarter of 2017, translating to a net loss per share of $0.52 in the second quarter of 2018. Its net loss per share was $0.66 in the second quarter of 2017. The decrease in net loss per share was due to an increase in the company’s outstanding shares, which increased from 17.04 million in the second quarter of 2017 to 34.45 million in the second quarter of 2018.
Its net loss per share was $0.17 in the second quarter of 2017. Six of them have given Sangamo stock a “buy” or higher rating, and one has rated it a “hold.” The mean rating for Sangamo stock is 1.71 with a target price of $27.83, implying an upside potential of 89.32% over its closing price of $14.70 on September 11. In comparison, peers Biogen (BIIB), BioMarin Pharmaceutical (BMRN), and Gilead Sciences (GILD) have mean ratings of 2, 1.78, and 2.15, respectively, and target prices of $389.20, $119.35, and $87.87, respectively.
Biogen (BIIB) enrolls first patient in a phase III study evaluating BIIB093 for prevention and treatment of severe cerebral edema in large hemispheric infarction.
Here's a look at the Boston biotech news you missed during your summer vacation: Alnylam gets historic FDA approval for first drug Cambridge's Alnylam Pharmaceuticals (Nasdaq: ALNY) received FDA approval for its first drug on Aug. 10, a first-ever treatment for a rare genetic disease that uses RNA interference to silence genes. The drug treats hereditary ATTR amyloidosis, which causes the liver to protein abnormal proteins that impede nervous system and organ functions. Marketed under the name Onpattro, it's the first RNA interference drug to be approved by the FDA.
The biotech sector performed well in August, with the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) up almost 3.5% this week alone. Research by Raymond James indicates that in just the past week, biotech ...
In the second quarter, BioMarin Pharmaceutical (BMRN) reported revenues of $372.8 million compared to $317.4 million in Q2 2017, reflecting a ~17% YoY (year-over-year) growth. It reported net revenues of $746.3 million in the first half of 2018 compared to $621.2 million in the first half of 2017, reflecting a ~2% YoY growth.
On August 30, BioMarin Pharmaceutical (BMRN) stock closed at $99.26, which is ~7% below its 52-week high of $106.20 on August 2. It hit its 52-week low of $75.81 on April 6.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Stocks hitting 52-week highs on Aug. 28) Abbott Laboratories (NYSE: ABT ) Affimed NV (NASDAQ: AFMD )(announced ...
The U.S. Moat Index posted strong performance again in July, and by the end of the month, its year-to-date results overtook the S&P 500 Index despite being underweight to the information technology sector. The U.S. Moat Index has been overweight healthcare companies for some time now as a result of the valuation dynamics in the sector. That positioning paid off in July with the top five performing constituents all coming from the sector.
Over the last six years, a small group of scientists working at different institutes have made incredible progress in a revolutionary new field called gene editing. Gene editing is just what it sounds like. It’s the changing — or “editing” — of an organism’s genes to produce a desired outcome.
Roche’s (RHHBY) Neurology segment generated revenues of 1.38 billion Swiss francs in the first half compared to 526.0 million Swiss francs in the first half of 2017, reflecting ~164% YoY (year-over-year) growth at CER (constant exchange rates). Roche’s neuroscience portfolio includes Ocrevus and Madopar.
Biogen (BIIB) reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.
Wall Street analysts expect Incyte (INCY) to report a 17.8% YoY (year-over-year) rise in sales to $1.81 billion in 2018 compared to $1.54 billion in 2017. Incyte is expected to report net adjusted income of $245.1 million in 2018 compared to net adjusted income of -$313.1 million in 2017. Incyte’s stock price has fallen nearly 42.4% over the last 12 months and nearly 26.5% year-to-date in 2018.
On its second-quarter earnings conference call, AbbVie (ABBV) raised its 2018 EPS guidance by $0.10. Considering the midpoint of this range, ABBV’s guidance is 39.5% higher YoY (year-over-year). AbbVie expects robust growth trends for its business in the second half of 2018 despite the expected entry of direct biosimilar competition for Humira in certain ex-US markets in the fourth quarter.
Analysts expect Allergan’s (AGN) adjusted EPS to be $16.29 on revenue of $15.53 billion in 2018, a 2.6% fall in revenue compared to $15.94 billion in 2017. Analysts expect the company’s adjusted net income to fall in 2018 mainly due to a fall in its gross profit margin and partially offset by a decrease in its selling, general, and administrative expenses as well as its research and development expenses. Allergan’s stock price has fallen nearly 20.2% over the last 12 months, but it’s risen ~12.8% year-to-date in 2018.
On August 17, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 8.5x, compared to the industry average PE of 12.1x. The company’s forward EV-to-EBITDA1, which is a capital structure–neutral valuation measure, is 10.8x. A stock’s forward PE ratio is calculated by dividing its current stock price by the next-12-month earnings estimate of the company.
Allergan (AGN) is developing a variety of products through internal programs as well as in collaboration with other companies. A few of the products it currently has under development are Cenicriviroc, Atogepant, Bimatoprost SR, Ubrogepant, Abicipar, Rapastinel, and Sarecycline.
As we discussed earlier, Amgen (AMGN) reported a 4% rise in its year-over-year revenue to ~$6.06 billion in the second quarter compared to $5.81 billion in the first quarter of 2017. Amgen surpassed analysts’ estimates for EPS and revenue in the second quarter, reporting non-GAAP (generally accepted accounting principles) EPS of $3.83 on revenue of ~$6.1 billion compared to the estimate of $3.54 on revenue of $5.7 billion.